Michael Gwarisa More than 7,400 patients in Japan have contributed to a breakthrough study identifying a hidden genetic mismatch that significantly increases the risk of life-threatening immune complications after umbilical cord blood transplantation. The research, led by Associate Professor Takakazu Kawase of Fujita Health University and the Japanese Society for Transplantation and Cellular Therapy (JSTCT)
Read More
Watch: Zimbabwe Launches Lenacapavir: New HIV Prevention Injection With 99.9% Protection Michael Gwarisa In a major step forward for HIV prevention, Zimbabwe has officially launched the rollout of Lenacapavir, a long-acting injectable drug that provides new protection options for communities at high risk of HIV infection. Zimbabwe joins South Africa, Kenya, Zambia, and Eswatini among
Read More
Michael Gwarisa After days of speculation and heightened public debate, Zimbabwe’s Medical Services Amendment Bill [H.B. 6A, 2025] has passed Parliament, but without the contentious Clause 11, which was formally deleted during the legislative process. The Bill was considered during the Committee Stage in the Parliament of Zimbabwe, where Clauses 1 to 10 were approved
Read More
Michael Gwarisa In a move aimed at strengthening collaboration to advance health security, workforce development, and resilient public health systems across Africa, the Africa Centres for Disease Control and Prevention has signed a Memorandum of Understanding (MoU) with FHI 360. The MoU sets in motion a structured framework for cooperation aligned with Africa CDC’s Strategic
Read More
Michael Gwarisa A daring local manufacturer of a herbal aphrodisiac, known as Hubaba, has come under fire for using the Medicines Control Authority of Zimbabwe (MCAZ) logo without the organisation’s consent. MCAZ is responsible for registering pharmaceutical products and consumables in Zimbabwe. However, a growing trend has emerged where herbal merchants and manufacturers falsely claim
Read More
Michael Gwarisa Zimbabwe has set the stage for the rollout of Lenacapavir, a long acting injectable HIV prevention medicine that is expected to significantly strengthen the country’s HIV response. The injectable drug, which is administered only twice a year, is being introduced as part of Zimbabwe’s expanded HIV prevention strategy targeting people at high risk
Read More
https://www.youtube.com/watch?v=hiEVMblYRrw  Michael Gwarisa In a major step toward improving the quality of cardiac care and reducing turnaround times for open heart surgeries in Zimbabwe, Parirenyatwa Group of Hospitals has commissioned a new heart bypass machine, also known as a heart lung machine. The brand new Stöckert S5 heart lung machine was procured by the
Read More
Michael Gwarisa Vaccines are temperature-sensitive biological products, and even small changes in temperature during storage or transport can significantly reduce their safety and effectiveness. While all vaccines are sensitive to heat, some can also be damaged by freezing or exposure to light. To ensure potency throughout the immunisation supply chain, the World Health Organization (WHO)
Read More
Michael Gwarisa United States President Donald Trump signed into law a US$5.88 billion bipartisan spending package on February 3, 2026 that restores and expands American support for global HIV initiatives, according to a statement from the Joint United Nations Programme on HIV/AIDS (UNAIDS). The package represents one of the largest single‑year pledges of U.S. government funding for the
Read More